Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient

Transplant Proc. 2010 Nov;42(9):3871-5. doi: 10.1016/j.transproceed.2010.07.090.

Abstract

Non-melanoma skin cancers (NMSCs) are the most common malignancies after solid organ transplantation. Their incidence increases with time after transplantation. Calcineurin-inhibitors (CNIs) and azathioprine are known as skin neoplasia-initiating and -enhancing immunosuppressants. In contrast, increasing clinical experience suggests a relevant antiproliferative effect of mammalian target of rapamycin inhibitors, also named proliferation signal inhibitors (PSIs). We report the case of a cardiac allograft recipient with an impressive and consolidated reduction of recurrent NMSC, observed after conversion from CNI-therapy to a PSI-based protocol.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcineurin Inhibitors*
  • Carcinoma, Squamous Cell / enzymology
  • Carcinoma, Squamous Cell / etiology*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy
  • Cell Proliferation / drug effects*
  • Drug Therapy, Combination
  • Everolimus
  • Heart Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Photochemotherapy
  • Signal Transduction / drug effects*
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use
  • Skin Neoplasms / enzymology
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Tacrolimus / adverse effects*
  • Time Factors
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus
  • Tacrolimus